Acthar and Injection site rash - a phase IV clinical study of FDA data

Summary:

Injection site rash is reported as a side effect among people who take Acthar (corticotropin), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Oxycodone, and have Nephrotic syndrome.

The phase IV clinical study analyzes which people have Injection site rash when taking Acthar. It is created by eHealthMe based on reports of 4,932 people who have side effects when taking Acthar from the FDA, and is updated regularly.

What is Acthar?

Acthar has active ingredients of corticotropin. eHealthMe is studying from 4,948 Acthar users. Check the latest studies of Acthar.

What is Injection site rash?

Injection site rash is found to be associated with 699 drugs and 713 conditions by eHealthMe. Check the latest studies of Injection site rash.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

4,932 people reported to have side effects when taking Acthar.
Among them, 21 people (0.43%) have Injection site rash.

Among these 21 people:

How long have people been on Acthar when they have Injection site rash? *

What is the gender of people who have Injection site rash when taking Acthar? *

female: 70 %
male: 30 %

What is the age of people who have Injection site rash when taking Acthar? *

What are other drugs people take besides Acthar? *

What are other side effects people have besides Injection site rash? *

Injection Site Pruritus (severe itching at injection site): 8 people, 38.10%
Injection Site Urticaria (rash of round, red welts on the skin at injection site): 5 people, 23.81%
Injection Site Pain: 5 people, 23.81%
Weight Increased: 5 people, 23.81%
Injection Site Erythema (redness at injection site): 5 people, 23.81%
Injection Site Bruising: 5 people, 23.81%
Injection Site Swelling: 4 people, 19.05%
Injection Site Vesicles (fluid- or air-filled cavity or sac at injection site): 4 people, 19.05%
Injection Site Reaction: 4 people, 19.05%
Malaise (a feeling of general discomfort or uneasiness): 4 people, 19.05%

What are the existing conditions these people have? *

Nephrotic Syndrome (kidney disease with proteinuria, hypoalbuminemia, and oedema): 4 people, 19.05%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 3 people, 14.29%
Uveitis (inflammation of the uvea): 1 person, 4.76%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 1 person, 4.76%
Sarcoidosis (an inflammatory disease that affects multiple organs in the body, but mostly the lungs and lymph glands): 1 person, 4.76%
Polyarthritis (arthritis which involves 5 or more joints simultaneously): 1 person, 4.76%
Optic Neuritis (optic nerve inflammation): 1 person, 4.76%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 4.76%
Iga Nephropathy (kidney disease- condition prevents the kidneys from filtering waste): 1 person, 4.76%
Glomerulonephritis Minimal Lesion (a disease of the kidney that causes nephrotic syndrome and usually affects children): 1 person, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Acthar and have Injection site rash?

- Check whether Injection site rash is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Acthar:

Acthar (4,948 reports)

Browse all side effects of Acthar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site rash:

Injection site rash (699 drugs)

Browse all the conditions that are associated with Injection site rash:

Injection site rash (713 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on corticotropin (the active ingredients of Acthar) and Acthar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.